logo
  

ABL Bio Enters Into Deal With Sanofi To Advance ABL301 For Parkinson's Disease Treatment

ABL Bio Inc. said that it has entered into collaboration and worldwide license agreement with Sanofi (SNYNF,SNY) to develop and commercialize ABL301, a pre-clinical stage bispecific antibody targeting alpha-synuclein and IGF1R to treat Parkinson's disease and other potential indications with enhanced blood-brain barrier or BBB penetration.

As per the terms of the deal, ABL will receive $75 million in upfront payments. In addition, ABL is eligible to receive up to $985 million based on the achievement of predefined development, regulatory and commercialization milestones, including $45 million in near-term milestones.

ABL is also eligible to receive royalties on net sales if the product from the collaboration is commercialized. The transaction will become effective after customary closing conditions are met, such as the HSR clearance.

Sanofi will receive worldwide exclusive development and commercialization rights to ABL301. Meanwhile, ABL will lead the preclinical development and Phase 1 clinical trial of ABL301.

Thereafter, Sanofi will be responsible for further clinical development, regulatory approval and commercialization of ABL301 worldwide.

Grabody-B is a BBB shuttling platform that targets the insulin-like growth factor 1 receptor (IGF1R) to maximize BBB penetration of potential therapies for various CNS-related diseases. Utilizing Grabody-B technology, ABL301 effectively carries the anti-alpha-synuclein antibody across the BBB to enhance therapeutic efficacy against Parkinson's disease.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the second quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided financial outlook for the third and the fourth quarters as well as slashed its guidance for the full-year 2023. For the third quarter, the company projects earnings in a range... American Airlines announced an agreement to purchase up to 20 Overture supersonic jets, the world's fastest airliner, from transportation start-up Boom Supersonic, with an option for an additional 40. Overture, which is expected to carry passengers at twice the speed of the fastest commercial aircraft available at present, would provide an important new speed advantage to American's fleet. WhatsApp, an instant messaging app owned by Meta Platforms, has launched a new desktop app for Windows users. The company is also developing an app native to Mac operating systems. Till now, WhatsApp Desktop users have been using its web-based desktop app i.e., WhatsApp Desktop, or browser-based app, i.e., WhatsApp Web. They were using the old Electron technology.
Follow RTT